–Reductions in dysmenorrhea (DYS) and non-menstrual pelvic pain (NMPP), the co-primary efficacy endpoints, compared to placebo were observed for both…
Tag: pricesensitive
ObsEva Announces Year End 2021 Financial Results and Provides Corporate Update
-Linzagolix for uterine fibroids: US NDA Q3:22 PDUFA date; Positive CHMP opinion- -Linzagolix for endometriosis: Reported positive topline results for…
ObsEva Enters into Licensing Agreement with Theramex for the Commercialization of Linzagolix
– Partnership leverages Theramex’s leading women’s health capabilities and commercial infrastructure to support the commercialization and market introduction of linzagolix…
ObsEva Provides Update on EU Marketing Authorisation Process for Linzagolix, an Oral GnRH Antagonist, for the Treatment of Uterine Fibroids
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – February 4, 2022 –…
ObsEva Appoints Katja Buhrer as Chief Strategy Officer
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – February 1, 2022 –…
ObsEva Announces Corporate Updates
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – January 28, 2022 –…
ObsEva Announces Positive Topline Results for Linzagolix 200 mg with Add-Back Therapy in the Phase 3 EDELWEISS 3 Trial in Patients with Moderate-to-Severe Endometriosis-Associated Pain
–Once daily linzagolix 200mg with ABTmet both co-primary efficacy objectives, demonstrating reductions in dysmenorrhea and non-menstrual pelvic pain versus placebo…
ObsEva Announces Positive CHMP Opinion for Linzagolix, an Oral GnRH Antagonist, for the Treatment of Uterine Fibroids
-European Commission Decision Anticipated in Q1 2022- -CHMP recommendation follows the recent acceptance of the linzagolix uterine fibroids NDA by…
ObsEva Appoints Will Brown as Chief Financial Officer
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – December 13, 2021…
ObsEva Hosts Symposium and Presents Clinical Data on Oral GnRH Antagonist Linzagolix at SEUD Congress 2021
-Symposium on oral GnRH antagonists and personalized therapeutic approaches for women with uterine fibroids to be hosted Friday, December 10…